Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE-07-MIBC: Disitamab Vedotin + Toripalimab vs Chemotherapy + Toripalimab in MIBC
NCT07608224Phase 3Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2026
- Primary completion
- Jun 2030
01
Overview
Phase 3, randomised, open-label trial of disitamab vedotin in muscle-invasive bladder cancer (MIBC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: 2-year Event-Free Survival. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT07608224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07608224.